1000TiP Novel next generation PARP1-selective and CNS penetrant inhibitor DSB2455: A phase Ia/Ib open label, multi-centre dose escalation study with expansion cohorts to assess the safety, tolerability, and activity as monotherapy in participants with advanced malignancies
Year: 2025
Type: article
Source: Annals of Oncology
Authors: R. Yarza, E. Garralda, V. Sánchez Perez, G.A. De Velasco Oria, P.M. Lorusso, R.M. Rodríguez, R.S. Kristeleit, A. Ring, C. Yap, J. Rekowski, P. Dickinson, L. Ruston, B. Mcguinness, P. Cowley, G. Campbell, A. Wise, C. Thomson, D. Landers, T.A. Yap
Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Universitario 12 De Octubre, Yale University, Hospital Universitario Reina Sofía, Guy's and St Thomas' NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415939776
FWCI:
Cites:
Cited by:
Related to: